Mutant prevention concentration of isoniazid, rifampicin and rifabutin against Mycobacterium tuberculosis

Chemotherapy

Volumn 51, Issue 2-3, 2005, Pages 76-79

  Rodriguez J C ^a   Cebrian L ^a   Ruiz, M ^a   Lopez M ^a   Royo, G ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Isoniazid; Mutant prevention concentration; Mycobacterium tuberculosis; Rifabutin; Rifampicin

Indexed keywords

ISONIAZID; RIFABUTIN; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; CONCENTRATION (PARAMETERS); INFECTION RISK; MONOTHERAPY; MUTANT PREVENTION CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; RIFABUTIN; RIFAMPIN;

EID: 22144470511     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085613     Document Type: Article

References (33)

1. Cohn DL: Treatment of latent tuberculosis infection: Renewed opportunity for tuberculosis control. Clin Infect Dis 2000;31:120-124.
2. Youngchaiyud P, Iseman MD: Update treatment of multidrug-resistant tuberculosis. Introduction, discussion and summary. Chemotherapy 1999;45(suppl2):1-2, 41-45.
3. Moreno S, Miralles P, Diaz MD, Baraia J, Padilla B, Berenguer J, Alberdi JC: Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival. Arch Intern Med 1997;157:1729-1734.
4. Chaisson RE: New developments in the treatment of latent tuberculosis. Int J Tuberc Lung Dis 2000;4(suppl 2):S176-S181.
5. Rodríguez JC, Ruiz M, Climent A, Royo G: In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 2001;17:229-231.
6. Rodríguez JC, Ruiz M, López M, Royo G: In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002;20:464-467.
7. Dong Y, Zhao X, Domagala J, Drlica K: Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999;43:1756-1758.
8. Dong Y, Zhao X, Kreiswirth BN, Drlica K: Mutant prevention concentration as a measure of antibiotic potency: Studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000;44:2581-2584.
9. Rodríguez JC, Cebrián L, López M, Ruiz M, Jiménez I, Royo G: Mutant prevention concentration: Comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 2004;53:441-444.
10. Fitzgerald DW, Morse MM, Pape JW, Johnson WD Jr: Active tuberculosis in individuals infected with human immunodeficiency virus after isoniazid prophylaxis. Clin Infect Dis 2000;31:1495-1497.
11. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE: Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998;113:1178-1183.
12. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, Weis S, King B, Shah N, Hodge T, Tuberculosis Trials Consortium: Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003;167:1341-1347.
13. Delahunty T, Lee B, Conte JE: Sensitive liquid chromatographic technique to measure isoniazid in alveolar cells, bronchoalveolar lavage and plasma in HIV-infected patients. J Chromatogr B Biomed Sci Appl 1998;705:323-329.
14. O'Brien JK, Doerfler ME, Harkin TJ, Rom WN: Isoniazid levels in the bronchoalveolar lavage fluid of patients with pulmonary tuberculosis. Lung 1998;176:205-211.
15. Peloquin CA, Namdar R, Dodge AA, Nix DE: Pharmacokinetics of isoniazid under tasting conditions, with food, and with antacids. Int J Tuberc Lung Dis 1999;3:703-710.
16. Product information Rifadin®, 2000.
17. Padgaonkar KA, Revankar SN, Bhatt AD, Vaz JA, Desai ND, D'Sa S, Shah V, Gandewar K: Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers. Int J Tuberc Lung Dis 1999;3:627-631.
18. Ziglam HM, Baldwin DR, Daniels I, Andrew JM, Finch RG: Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibreoptic bronchoscopy. J Antimicrob Chemother 2002;50:1011-1015.
19. Kiss IJ, Farago E, Juhaz I, Bacsa S, Fabian E: Investigation on the serum and lung tissue level of rifampicin in man. Int J Clin Pharmacol Biopharm 1976;13:42-47.
20. Li RC, Nightingale S, Lewis RC, Colborn DC, Narang PK: Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. Antimicrob Agents Chemother 1996;40:1397-1402.
21. Mitchison DA: How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998;2:10-15.
22. Conte JE Jr, Golden JA, McQuitty M, Kipps J, Duncan S, McKenna E, Zurlinden E: Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. Antimicrob Agents Chemother 2002;46:2358-2364.
23. Weber WW, Hein DW: Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet 1979;4:401-422.
24. Sahai J, Gallicano K, Swick L, Tailor S, Garber G, Seguin I, Oliveras L, Walker S, Rachlis A: Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997;127:289-293.
25. Choudhri SH, Hawken M, Gathua S: Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. Clin Infect Dis 1997;25:104-111.
26. Martinez Alfaro EM, Cuadra F, Solera J, Macia MA, Geijo P, Sanchez Martinez PA, Rodriguez Zapata M, Largo J, Sepulveda MA, Rosa C, Sanchez L, Espinosa A, Mateos F, Blanch JJ: Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus. The GECMEI Group. Med Clin (Barc) 2000;115:161-165.
27. Whalen CC, Johnson JL, Okwera A, Horn DL, Huebner R, Mugyenyi P, Mugerwa RD, Ellner JJ: A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997;337:801-808.
28. Matteelli A, Olliaro P, Signorini L, Cadeo G, Scalzini A, Bonazzi L, Caligaris S, Tomasoni L, Tebaldi A, Carosi G: Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: A pilot study. Int J Tuberc Lung Dis 1999;3:1043-1046.
29. Polesky A, Farber HW, Gottlieb DJ, Park H, Levinson S, O'Connell JJ, McInnis B, Nieves RL, Bernardo J: Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996;154:1473-1477.
30. Villarino ME, Ridzon R, Weismuller PC, Elcock M, Maxwell RM, Meador J, Smith PJ, Carson ML, Geiter LJ: Rifampin preventive therapy for tuberculosis infection: Experience with 157 adolescents. Am J Respir Crit Care Med 1997;155:1735-1738.
31. Blaschke TF, Skinner MH: The clinical pharmacokinetics of rifabutin. Clin Infect Dis 1996;22(suppl 1):S15-S21.
32. Grassi C, Peona V: Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis 1996;22(suppl 1):S50-S54.
33. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 2000;49:185-189.